Bone targeted new zoledronate derivative: design, synthesis, ^99mTc-coupling, in-silico study and preclinical evaluation for promising osteosarcoma therapy

References

• Al-Wabli RI, Sakr TMMH, Khedr MA, Selim AA, El M-M, Zaghary WA. 2016. Platelet-12 lipoxygenase targeting via a newly synthesized curcumin derivative radiolabeled with technetium-99m. Chem Cent J. 10(1):1–12.
   PubMedGoogle Scholar
• Aljuhr SA, Abdelaziz G, Essa BM, Zaghary WA, Sakr TM. 2021. Hepatoprotective, antioxidant and anti-inflammatory potentials of Vit-E/C@SeNPs in rats: synthesis, characterization, biochemical, radio-biodistribution, molecular and histopathological studies. Bioorg Chem. 117:105412.
   PubMed Web of Science ®Google Scholar
• Anderson PM, Subbiah V, Rohren E. 2014. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Curr Adv Osteosarcoma. 804:291–304.
   Google Scholar
• Berenson JR. 2005. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 10(1):52–62.
   PubMed Web of Science ®Google Scholar
• Body J-J. 2003. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. The Breast. 12:S37–S44.
   PubMed Web of Science ®Google Scholar
• Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, et al. 1998. Current use of bisphosphonates in oncology. International bone and cancer study group. J Clin Oncol. 16(12):3890–3899.
   PubMed Web of Science ®Google Scholar
• Bouman-Wammes EW, de Klerk JM, Bloemendal HJ, Van Dodewaard-de Jong JM, Lange R, Ter Heine R, Verheul HM, Van den Eertwegh AJ. 2019. Bone-targeting radiopharmaceuticals as monotherapy or combined with chemotherapy in patients with castration-resistant prostate cancer metastatic to bone. Clin Genitourin Cancer. 17(2):e281–e292.
   PubMed Web of Science ®Google Scholar
• Breitz H, Wendt R, Stabin M, Bouchet L, Wessels B. 2003. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP. Cancer Biother Radiopharm. 18(2):225–230.
   PubMed Web of Science ®Google Scholar
• Brenner W, Kampen WU, Kampen AM, Henze E. 2001. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med. 42(2):230–236.
   PubMed Web of Science ®Google Scholar
• Bruland ØS, Larsen RH. 2013. Treatment of osteoblastic skeletal metastases by the alpha-emitting bone-seeker radium-223. In: Baum R. (eds) Therapeutic Nuclear Medicine. Medical Radiology. Berlin, Heidelberg: Springer.
   Google Scholar
• Cheng H-L, Lin C-W, Yang J-S, Hsieh M-J, Yang S-F, Lu K-H. 2016. Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways. Oncotarget. 7(9):9742–9758.
   PubMedGoogle Scholar
• Curtis KK, Wong WW, Ross HJ. 2016. Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck. Crit Rev Oncol Hematol. 103:86–98.
   PubMed Web of Science ®Google Scholar
• Fischer M, Kampen WU. 2012. Radionuclide therapy of bone metastases. Breast Care (Basel). 7(2):100–107.
   PubMed Web of Science ®Google Scholar
• Geskovski N, Kuzmanovska S, Simonoska Crcarevska M, Calis S, Dimchevska S, Petrusevska M, Zdravkovski P, Goracinova K. 2013. Comparative biodistribution studies of technetium-99 m radiolabeled amphiphilic nanoparticles using three different reducing agents during the labeling procedure. J Labelled Comp Radiopharm. 56(14):689–695.
   PubMed Web of Science ®Google Scholar
• Gillings N, Todde S, Behe M, Decristoforo C, Elsinga P, Ferrari V, Hjelstuen O, Peitl PK, Koziorowski J, Laverman P, et al. 2020. EANM guideline on the validation of analytical methods for radiopharmaceuticals. EJNMMI Radiopharm Chem. 5(1):1–29.
   Google Scholar
• Gong L, Altman RB, Klein TE. 2011. Bisphosphonates pathway. Pharmacogenet Genomics. 21(1):50–53.
   PubMed Web of Science ®Google Scholar
• Green JR. 2003. Antitumor effects of bisphosphonates. Cancer: Interdiscip Int J Am Cancer Soc. 97(3 Suppl):840–847.
   Google Scholar
• Günay NS, Çapan G, Ulusoy N, Ergenç N, Ötük G, Kaya D. 1999. 5-Nitroimidazole derivatives as possible antibacterial and antifungal agents. Farmaco. 54(11-12):826–831.
   PubMedGoogle Scholar
• Handkiewicz-Junak D, Poeppel TD, Bodei L, Aktolun C, Ezziddin S, Giammarile F, Delgado-Bolton RC, Gabriel M. 2018. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging. 45(5):846–859.
   PubMed Web of Science ®Google Scholar
• Hay MP, Lee HH, Wilson WR, Roberts PB, Denny WA. 1995. Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility. J Med Chem. 38(11):1928–1941.
   PubMed Web of Science ®Google Scholar
• Hazari PP, Chuttani K, Kumar N, Mathur R, Sharma R, Singh B, Mishra AK. 2009. Synthesis and biological evaluation of isonicotinic acid hydrazide conjugated with diethyelenetriaminepentaacetic acid for infection imaging. TONMEDJ. 1(1):33–42.
   Google Scholar
• Janjan N. 2001. Bone metastases: approaches to management. Semin Oncol. 28(4 Suppl 11):28–34.
   PubMed Web of Science ®Google Scholar
• Kauerova T, Kos J, Gonec T, Jampilek J, Kollar P. 2016. Antiproliferative and pro-apoptotic effect of novel nitro-substituted hydroxynaphthanilides on human cancer cell lines. IJMS. 17(8):1219.
   Google Scholar
• Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, Elbling L, Sutterlüty H, Scotlandi K, Kotz R, et al. 2006. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res. 24(6):1145–1152.
   PubMed Web of Science ®Google Scholar
• Lange R, Ter Heine R, Knapp RF, de Klerk JM, Bloemendal HJ, Hendrikse NH. 2016. Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases. Bone. 91:159–179.
   PubMed Web of Science ®Google Scholar
• Lipton A. 2003. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs. 8(2):469–488.
   PubMedGoogle Scholar
• Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Ortu Kowalski M, Reitsma D, Seaman J. 2002. The new bisphosphonate, Zometa®(zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Investig. 20(sup2):45–54.
   PubMed Web of Science ®Google Scholar
• Mercadante S. 1997. Malignant bone pain: pathophysiology and treatment. Pain. 69(1-2):1–18.
   PubMed Web of Science ®Google Scholar
• Mital A. 2009. Synthetic nitroimidazoles: biological activities and mutagenicity relationships. Sci Pharm. 77(3):497–520.
   Google Scholar
• Motaleb M, Sanad M, Selim A, El-Tawoosy M, Abd-Allah M. 2018. Synthesis, characterization, and radiolabeling of heterocyclic bisphosphonate derivative as a potential agent for bone imaging. Radiochemistry. 60(2):201–207.
   Web of Science ®Google Scholar
• Motaleb M, Selim AA, El-Tawoosy M, Sanad M, El-Hashash M. 2018. Synthesis, characterization, radiolabeling and biodistribution of a novel cyclohexane dioxime derivative as a potential candidate for tumor imaging. Int J Radiat Biol. 94(6):590–596.
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Schmidt RL, Stockler MR. 2005. Bisphosphonates for breast cancer. Cochrane Database of Syst Rev. 20;(3):CD003474.
   Google Scholar
• Perry CM, Figgitt DP. 2004. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs. 64(11):1197–1211.
   PubMed Web of Science ®Google Scholar
• Qiu L, Cheng W, Lin J, Luo S, Xue L, Pan J. 2011. Synthesis and biological evaluation of novel (99m)Tc-labelled bisphosphonates as superior bone imaging agents. Molecules. 16(8):6165–6178.
   PubMed Web of Science ®Google Scholar
• Rosen L, Harland SJ, Oosterlinck W. 2002. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol. 25(6 Suppl 1):S19–S24.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ. 2001. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J (Sudbury, Mass). 7(5):377–387.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, et al. 2003. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol. 21(16):3150–3157.
   PubMed Web of Science ®Google Scholar
• Sakr T, Essa B, El-Essawy F, El-Mohty A. 2014. Synthesis and biodistribution of 99m Tc-PyDA as a potential marker for tumor hypoxia imaging. Radiochemistry. 56(1):76–80.
   Google Scholar
• Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson D, Golub E, Rodan G. 1991. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 88(6):2095–2105.
   PubMed Web of Science ®Google Scholar
• Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, Mangialardi G, Bertieri R, Coluccia AML, Ribatti D, et al. 2007. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther. 6(12 Pt 1):3256–3262.
   PubMed Web of Science ®Google Scholar
• Siim BG, Denny WA, Wilson WR. 1997. Nitro reduction as an electronic switch for bioreductive drug activation. Oncol Res Featur Preclin Clin Cancer Ther. 9(6–7):357–369.
   Google Scholar
• Silvestri R, Artico M, De Martino G, Ragno R, Massa S, Loddo R, Murgioni C, Loi AG, La Colla P, Pani A. 2002. Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptase. J Med Chem. 45(8):1567–1576.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Iwasaki M, Murata-Hirai K, Matsumoto K, Hayashi K, Okamura H, Sugie T, Minato N, Morita CT, Toi M. 2017. Anti-tumor activity and immunotherapeutic potential of a bisphosphonate prodrug. Sci Rep. 7(1):1–13.
   PubMedGoogle Scholar
• Tenta R, Pitulis N, Tiblalexi D, Consoulas C, Katopodis H, Konstantinidou E, Manoussakis M, Kletsas D, Alexis MN, Poyatzi A, et al. 2008. Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells. Horm Metab Res. 40(11):737–745.
   PubMed Web of Science ®Google Scholar
• Wilson WR, Van Zijl P, Denny WA. 1992. Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. Int J Radiat Oncol Biol Phys. 22(4):693–696.
   PubMed Web of Science ®Google Scholar
• Żwawiak J, Zaprutko L. 2018. The structure and activity of double-nitroimidazoles. A mini-review. Sci Pharm. 86(3):30.
   Web of Science ®Google Scholar